Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited [NSE: PIRHEALTH, BSE: 500302], will present data on several compounds from its molecular imaging portfolio at the Society of
Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13. Data from five florbetaben studies will be featured, including results from a pivotal Phase III trial which will provide the basis for regulatory submission later this year.
Earlier this spring, Piramal Imaging was formed through the acquisition of worldwide rights to the molecular imaging research and development portfolio of Bayer Pharma AG. Florbetaben, a late-stage amyloid imaging agent being studied as a potential tool to aid in the diagnosis and assessment of Alzheimer's disease, is the lead compound in the portfolio.
Historically, the only way to definitively diagnose Alzheimer's disease has been after death - at autopsy - through analysis and identification of beta-amyloid in brain tissue. The global Phase III trial employed a unique and rigorous study design comparing in vivo brain positron emission tomography (PET) imaging with florbetaben to post-mortem analysis of the brain tissue. Another study compared florbetaben scans of people with mild cognitive impairment (MCI) over time to assess their risk of developing Alzheimer's disease.